Company: AZN
Filing Date: 2025-04-11
Form Type: 6-K
Source: 0001654954-25-004150
Chunk: 1

Company: ASTRAZENECA PLC
Filing Date: 2025-04-11
Form: 6-K
Chunk 1
---
 pre-emption rights   
 for acquisitions and specified capital investments                  | 1,011,405,311 |           84.89 |   179,961,211 |           15.11 |       1,191,366,522 |                                           76.83 |      6,556,062 |
| 11 | To authorise the Company to purchase its own shares                 | 1,186,436,265 |           99.24 |     9,028,112 |            0.76 |       1,195,464,377 |                                           77.10 |      2,458,408 |
| 12 | To reduce the notice period for general meetings                    | 1,109,717,539 |           92.81 |    85,989,258 |            7.19 |       1,195,706,797 |                                           77.11 |      2,216,021 |

Deborah DiSanzo and Andreas Rummelt retired from the Board at the conclusion of the AGM. For the purposes of section 430(2B) of the Companies Act 2006, they will receive their pro-rata entitlement to non-executive director fees for the month of April 2025. No other remuneration payment or payment for loss of office will be made.

A copy of the resolutions passed at the AGM (other than resolutions concerning ordinary business) has been submitted to the National Storage Mechanism for publication, and will shortly be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism .

#### I ssued capital
As at 9 April 2025, the number of issued shares of the Company was 1,550,636,615 ordinary shares, which was the total number of shares entitling the holders to attend and vote for or against all of the resolutions at the AGM. In accordance with the Company's Articles of Association, on a poll every member present in person or by proxy has one vote for every share held.

#### AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.